August 28, 2015

Interim Report second quarter and first half year 2015

Highlights

Targovax entered into an agreement with the shareholders of Oncos Therapeutics Oy to acquire the shares of Oncos creating a Nordic leader within immuno-oncology
Targovax announced a successful private placement of NOK 200 million. The amount was raised from NOK 125-150 million thanks to substantial investor interest. The new issue was completed after the end of Q2.
Targovax presented interim data from the ongoing phase I/II clinical study of TG01 at the annual meeting of American Society of Clinical Oncology (ASCO 2015) indicating that about 80% or more of the patients mount an immune response to the therapeutic cancer vaccine
A new board of directors was elected at the extraordinary general meeting in late June: Jonas Einarsson (chair), Bente-Lill Romøren, Lars Lund-Roland, Per Samuelsson, Robert Burns and Johan Christenson
Appointment of Øystein Soug as CFO and Peter Skorpil as Head of Business Development